Background: Carbon monoxide (CO) is known as silent killer; since it is a colorless, odorless and non-irritating but
highly toxic gas. It results from incomplete combustion of carbonaceous substances. The current method for CO
poisoning begins with clinical suspicion and a review of the patient's medical history. It is then confirmed by detecting
elevated CO-Hb levels (greater than 10%), which can be measured through invasive blood gas analysis or non-invasive
techniques like multi-wave pulse oximetry. Objective: we summarize recent advances in understanding challenges in
early diagnosis of CO induced cardiotoxicity and neurotoxicity. Traditional diagnostic markers such as cardiac enzymes,
ECG, and brain CT scans remain essential for diagnosing CO-induced cardiotoxicity and neurotoxicity. Emerging
biomarkers like heart-type fatty acid-binding protein (H-FABP) and neurogranin show potential for earlier and more
accurate detection of CO poisoning-related organ damage. Conclusions: Recent markers are needed for early detection
of acute in CO induced cardiotoxicity and neurotoxicity other than traditional markers |
